India, July 14 -- The University of Oxford's Oxford Vaccine Group has launched the world's first Phase I clinical trial, BD-Ebov, of a vaccine against Bundibugyo ebolavirus (BDBV), in response to the ongoing outbreak in the Democratic Republic of the Congo and neighbouring Uganda.

Conducted in Oxford, the trial will assess the safety and immune response of the ChAdOx1 BDBV vaccine in 50 healthy adults aged 18-55 years. Recruitment of volunteers into the study is now underway, where they will then attend screening visits. In the coming weeks, and following regulatory review for trial commencement, participants will then be vaccinated and attend follow-up visits in Oxford.

To support the rapid launch of the study and progression of the va...